TMO at a glance
Thermo Fisher Scientific (TMO, SEC CIK 97745) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Thermo Fisher Scientific (TMO) reported revenue of $44.6 billion (up 3.9% from FY2024) and net income of $6.7 billion. Diluted EPS was $17.74.
- As of September 30, 2026, 63 institutional investment managers tracked by SignalX reported holding Thermo Fisher Scientific (TMO) shares worth $96.3 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Pettiti Gianluca on November 13, 2026 of 400 shares at $701.42 per share.
- In the last 90 days, TMO insiders reported 0 open-market purchases ($0) and 9 open-market sales ($7.6M) on Form 4, a net sale of $7.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $44.6B
- +3.9% vs prior year
- Insiders · 90 days
- 0 buys · 9 sells
- Net −$7.6M
- 13F holders
- 63 funds
- $96.3B · −3 vs prior quarter
- Latest 8-K
- Oct 30, 2026
- Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Management Discussion & Analysis
- Revenue $44,556M, up ~3.9% YoY from $42,879M; Lab Products & Biopharma Services largest segment at $23,984M
- GAAP operating margin 17.4% vs 17.1%; adjusted operating margin 22.7% vs 22.6%; driven by productivity gains offset by tariffs and mix
- Best segment: Specialty Diagnostics margin 26.9% vs 25.7% (+1.2pt); worst: Analytical Instruments margin 23.0% vs 26.2% (-3.2pt) hit by tariffs
- Free cash flow $6,337M vs $7,324M; capex $1,525M; buybacks $3.0B (5.8M shares); dividends $0.64B; total debt rose to $39.4B from $31.3B
- 2026 capex guided $1.8B–$2.0B; GAAP tax rate 7%–9%; risks include academic/government spending hesitancy, China macro weakness, tariff impacts
Business Overview
- Core business: Life sciences tools & services conglomerate serving pharma/biotech, academic, industrial, and healthcare markets across four segments
- Sept 2025 acquisition of Solventum's filtration/separation business (~$4.04B total acquisition spend in 2025) added bioproduction purification tech plus industrial filtration for battery, semiconductor, and medical device markets
- Revenue $44.6B in 2025, up ~4% YoY; adjusted EPS $22.87 vs $21.86; Analytical Instruments segment margin compressed to 23.0% from 26.2% due to tariff impacts and FX headwinds
- Total debt surged to $39.4B from $31.3B YoY, while cash jumped to $9.85B from $4.0B, reflecting $7.76B new debt issuance; $5B share buyback authorized Nov 2025
- Federal government shutdown noted in Oct 2025 as a specific demand risk, with academic/government revenue explicitly declining due to U.S. policy uncertainty and China macro weakness
Risk Factors
- China regulations requiring local suppliers plus tariff volatility directly threaten international revenues, with currency translation adding $0.37B to 2025 revenues
- Outstanding debt ~$39.38B with $5.00B revolving credit facility; covenant requires minimum 3.5:1.0 Consolidated Net Interest Coverage Ratio
- Goodwill and indefinite-lived intangibles total ~$50.59B ($49.36B + $1.23B) on balance sheet, vulnerable to impairment if acquisitions underperform
- FDA and DEA regulatory exposure: sole manufacturer for numerous pharma customers, meaning single negative regulatory event disrupts multiple downstream supply chains
- Sole/limited-source suppliers for certain materials; no quick qualification of replacements if supplier exits, faces bankruptcy, or is hit by sanctions
AI summary of the TMO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 26, 2026
Risk Factors
- No material changes identified from the December 31, 2025 Form 10-K
- Carried-forward risks remain detailed in the company’s 2025 Annual Report
Management Discussion & Analysis
- Revenue $12,137M, up from $11,122M YoY; Laboratory Products and Biopharma Services led contributions
- GAAP operating margin 18.6% vs 17.4%; adjusted margin 24.5% vs 23.3%
- Best segment: Laboratory Products and Biopharma Services revenue $6,863M vs $5,970M, margin 15.5% vs 14.5%
- Worst segment: Specialty Diagnostics revenue $1,098M vs $1,174M; margin 31.0% vs 27.4%
- Cash $5,461M vs $9,852M; operating cash flow $5,867M, free cash flow $4,618M, acquisitions $8.88B
AI summary of the TMO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Executive Vice President Michael D. Shafer retiring effective December 31, 2026
- Leadership transition may affect oversight of Shafer’s business responsibilities
Item 2.02: Results of Operations and Financial Condition
- Q3 fiscal 2026 results announced October 21, 2026
- Reporting period ended September 26, 2026
Item EX-99.1: Item EX-99.1
- Q3 revenue $12.14B, up 9%, with 6% organic growth, indicating broad underlying demand beyond acquisitions and divestitures
- GAAP diluted EPS $4.64, up 9%; adjusted EPS $6.68, up 15%, showing stronger earnings growth after acquisition-related adjustments
Item 2.02: Results of Operations and Financial Condition
- Q2 fiscal 2026 results announced for quarter ended June 27, 2026
- Full financial results and management commentary furnished in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue rose 10% to $11.99B, including 5% organic growth, signaling broadening customer demand across end markets
- Adjusted EPS increased 13% to $6.03, while adjusted operating margin expanded to 22.8% from 21.9%
AI summaries of TMO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TMO
Don't miss the next TMO filing
- Alerts as it files. A push when TMO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TMO, by share count.
- Ask anything. An AI agent that reads every TMO filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Pettiti Gianluca | Sell | Nov 13, 2026 | 400 | $701.42 |
| Pettiti Gianluca | M | Nov 13, 2026 | 3,733 | $309.63 |
| Pettiti Gianluca | M | Nov 13, 2026 | 3,733 | - |
| Pettiti Gianluca | Sell | Nov 13, 2026 | 3,733 | $701.42 |
| Britt Lisa P. | Sell | Oct 28, 2026 | 2,831 | $706.45 |
| SPERLING SCOTT M | G | Oct 28, 2026 | 3,490 | - |
| SPERLING SCOTT M | A | Sep 26, 2026 | 62.96 | - |
| JOHNSON JENNIFER M | A | Sep 26, 2026 | 46.3 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $42.9B | $42.9B | $44.6B |
| Operating Income | - | $7.3B | $7.7B |
| Net Income | $6.0B | $6.3B | $6.7B |
| Op. Margin | - | 17.1% | 17.4% |
| Net Margin | 14.0% | 14.8% | 15.0% |
| Balance Sheet | |||
| Total Assets | - | $97.3B | $110.3B |
| Equity | $46.7B | $49.6B | $53.4B |
| ROE | 12.8% | 12.8% | 12.6% |
| Per Share | |||
| EPS | - | $16.53 | $17.74 |
| Cash Flow | |||
| Operating CF | - | $8.7B | $7.8B |
| CapEx | $1.5B | $1.4B | $1.5B |
Source: XBRL data in Thermo Fisher Scientific (TMO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate TMO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 63 | $96.33B |
| Q2 2026 | 66 | $76.49B |
| Q1 2026 | 68 | $73.35B |
| Q4 2025 | 63 | $85.28B |
| Q3 2025 | 63 | $75.12B |
| Q2 2025 | 61 | $57.76B |
| Q1 2025 | 60 | $53.08B |
| Q4 2024 | 57 | $42.19B |
- JPMorgan Chase & Co+1.93M (+23%)
- BlackRock+1.25M (+4%)
- T. Rowe Price Group+1.18M (+23%)
- Ameriprise Financial+517.0K (+33%)
- Goldman Sachs Group+297.4K (+10%)
- Viking Global Investors−1.02M (-53%)
- D.E. Shaw & Co−469.1K (-73%)
- Citadel Advisors LLC−425.3K (-74%)
- Franklin Resources−248.9K (-3%)
- Morgan Stanley−244.7K (-2%)
- FMR LLC (Fidelity)−14.08M
- Ally Financial Inc−17.0K
- Equitable Holdings Inc−14.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 501 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TMO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Oct 30, 2026 | - | - | - |
| 4 | Oct 30, 2026 | - | - | - |
| 8-K | Oct 30, 2026 | - | Analysis | - |
| 10-Q | Oct 30, 2026 | Sep 26, 2026 | Analysis | |
| 8-K | Oct 21, 2026 | - | Analysis | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- ACHC · Acadia Healthcare Company IncServices-Specialty Outpatient Facilities, NEC
TMO SEC filings: frequently asked questions
Are TMO insiders buying or selling?
In the last 90 days, Thermo Fisher Scientific (TMO) officers, directors and 10% owners reported no open-market purchases and 9 open-market sales worth $7.6 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TMO stock?
As of September 30, 2026, the largest Thermo Fisher Scientific (TMO) holders among the 13F filers tracked by SignalX were BlackRock ($21.7 billion), Vanguard Capital Management LLC ($16.3 billion), State Street Corp ($11.4 billion), Morgan Stanley ($7.1 billion), JPMorgan Chase & Co ($7.1 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TMO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Thermo Fisher Scientific (TMO) reported revenue of $44.6 billion (up 3.9% from FY2024) and net income of $6.7 billion. Diluted EPS was $17.74. The figures come from the XBRL data in the 10-K.
What are the main risks in TMO's latest 10-K?
In the 10-K filed February 26, 2026, Thermo Fisher Scientific (TMO) flagged: China regulations requiring local suppliers plus tariff volatility directly threaten international revenues, with currency translation adding $0.37B to 2025 revenues. Outstanding debt ~$39.38B with $5.00B revolving credit facility; covenant requires minimum 3.5:1.0 Consolidated Net Interest Coverage Ratio. (AI summary of the Risk Factors section.)
What did TMO report in its latest 8-K?
Thermo Fisher Scientific (TMO) filed an 8-K on October 30, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Executive Vice President Michael D. Shafer retiring effective December 31, 2026.
What are the latest TMO SEC filings?
Thermo Fisher Scientific (TMO) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and a Form 4 insider filing on November 16, 2026.
What is TMO's SEC CIK number?
Thermo Fisher Scientific (TMO)'s SEC Central Index Key (CIK) is 97745. EDGAR lists every TMO filing under that number.
Ask anything about TMO
The research agent reads TMO's filings, financials, insider trades and 13F holders, then answers with sources.